Elsevier

Clinical Therapeutics

Volume 25, Issue 2, February 2003, Pages 342-395
Clinical Therapeutics

Review article
Thalidomide: A review of approved and investigational uses

https://doi.org/10.1016/S0149-2918(03)80085-1Get rights and content

Abstract

Background: Thalidomide is best known as a major teratogen that caused birth defects in up to 12,000 children in the 1960s. More recently, this agent has been approved by the US Food and Drug Administration for the treatment of erythema nodosum leprosum (ENL) through a restricted-use program. Its immunomodulatory, anti-inflammatory, and antiangiogenic properties are currently under study in a number of clinical conditions.

Objective: This article reviews the pharmacology of thalidomide; its approved and off-label uses in dermatologic, oncologic, and gastrointestinal conditions; and adverse events associated with its use.

Methods: Relevant articles were identified through searches of MEDLINE (1966–June 2002), International Pharmaceutical Abstracts (1970–June 2002), and EMBASE (1990–June 2002). Search terms included but were not limited to thalidomide, pharmacokinetics, pharmacology, therapeutic use, and teratogenicity, as well as terms for specific disease states and adverse events. Further publications were identified from the reference lists of the reviewed articles. Abstracts of recent symposia were obtained from the American Society of Clinical Oncology Web site.

Results: Thalidomide is thought to exert its therapeutic effect through the modulation of cytokines, particularly tumor necrosis factor-α. In addition to its approved indication for ENL, thalidomide has been studied in various other conditions, including graft-versus-host disease, discoid lupus erythematosus, sarever, the ulcers return on drug discontinuation, leading to concerns about long-term use of thalidomide and the risk of peripheral neuropathy. The preliminary results of thalidomide use in patients with Crohn's disease are encouraging; however, further studies are necessary. Case reports and studies in small numbers of patients have shown effectiveness for thalidomide in other clinical conditions.

Because thalidomide is highly teratogenic, guidelines for its use must be followed carefully. Thalidomide is a toxic medication, and therapeutic and well-tolerated doses have not been established for any condition except ENL. Because long-term use of thalidomide carries a risk of irreversible peripheral neuropathy and because the neuropathy may be asymptomatic, routine testing is necessary. Efforts to develop agents that retain the efficacy of thalidomide without its unwanted effects are ongoing.

References (221)

  • T. Hideshima et al.

    Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy

    Blood

    (2000)
  • H. Geitz et al.

    Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade

    Immunopharmacology

    (1996)
  • S.G. Browne

    Erythema nodosum in leprosy

    J Chronic Dis.

    (1963)
  • A.C. Nogueira et al.

    Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells

    Life Sci.

    (1994)
  • M. Arora et al.

    Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease

    Biol Blood Marrow Transplant

    (2001)
  • P.M. Parker et al.

    Thalidomide as salvage therapy for chronic graft-versus-host disease

    Blood

    (1995)
  • S. Koc et al.

    Thalidomide for treatment of patients with chronic graft-versus-host disease

    Blood

    (2000)
  • M. Carlesimo et al.

    Treatment of cutaneous and pulmonary sarcoidosis with thalidomide

    J Am Acad Dermatol.

    (1995)
  • S.J. Oliver et al.

    Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement

    Clin Immunol.

    (2002)
  • S.J. Oliver et al.

    Immune stimulation in scleroderma patients treated with thalidomide

    Clin Immunol.

    (2000)
  • S.J. George et al.

    Lichen planopilaris treated with thalidomide

    J Am Acad Dermatol.

    (2001)
  • G.L. Federman et al.

    Recalcitrant pyoderma gangrenosum treated with thalidomide

  • P. Wolkenstein et al.

    Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis

    Lancet

    (1998)
  • B. Barlogie et al.

    Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a Phase 2 study of 169 patients

    Blood

    (2001)
  • J. Bladé et al.

    Thalidomide in refractory and relapsing multiple myeloma

    Semin Oncol.

    (2001)
  • E.M. Tansey

    Dark Remedy. The Impact of Thalidomide and Its Revival as a Vital Medicine

    N Engl J Med.

    (2001)
  • J. Sheskin

    Thalidomide in the treatment of lepra reactions

    Clin Pharmacol Ther.

    (1965)
  • J. Sheskin et al.

    Results of a double blind study of the influence of thalidomide on the lepra reaction

    Int J Lepr Other Mycobact Dis.

    (1969)
  • Thalomid capsules

    (2001)
  • T. Eriksson et al.

    Intravenous formulations of the enantiomers of thalidomide: Pharmacokinetic and initial pharmacodynamic characterization in man

    J Pharm Pharmacol.

    (2000)
  • T. Eriksson et al.

    Enantiomers of thalidomide: Blood distribution and the influence of serum albumin on chiral inversion and hydrolysis

    Chirality

    (1998)
  • T. Eriksson et al.

    Handling of blood samples for determination of thalidomide

    Clin Chem.

    (1997)
  • T. Eriksson et al.

    Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide

    Chirality

    (1995)
  • S.K. Teo et al.

    Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers

    J Clin Pharmacol.

    (1999)
  • C.B. Trapnell et al.

    Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone

    Clin Pharmacol Ther.

    (1998)
  • M.R. Scheffler et al.

    Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics

    Clin Pharmacol Ther.

    (1999)
  • F.H. Noormohamed et al.

    Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects

    AIDS Res Hum Retroviruses

    (1999)
  • S.K. Teo et al.

    Thalidomide dose proportionality assessment following single doses to healthy subjects

    J Clin Pharmacol.

    (2001)
  • S.K. Teo et al.

    Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women

    Biopharm Drug Dispos.

    (2000)
  • F. Aweeka et al.

    Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG Protocol 251

    J Clin Pharmacol.

    (2001)
  • D.A. Wohl et al.

    Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267

    J Infect Dis.

    (2002)
  • D. Heney et al.

    Thalidomide treatment for chronic graft-versus-host disease

    Br J Haematol.

    (1991)
  • B.J. Boughton et al.

    High-performance liquid chromatographic assay of plasma thalidomide: Stabilization of specimens and determination of a tentative therapeutic range for chronic graft-versus-host disease

    Ann Clin Biochem.

    (1995)
  • T. Eriksson et al.

    Low bioavailability of rectally administered thalidomide

    Am J Health Syst Pharm.

    (2000)
  • S.K. Teo et al.

    Thalidomide is distributed into human semen after oral dosing

    Drug Metab Dispos.

    (2001)
  • S.K. Teo et al.

    Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients

    J Biochem Mol Toxicol.

    (2000)
  • H. Schumacher et al.

    The metabolism of thalidomide: The fate of thalidomide and some of its hydrolysis products in various species

    Br J Pharmacol.

    (1965)
  • R.T. Williams et al.

    The chemistry and metabolism of thalidomide

  • G.F. Somers

    Pharmacologic properties of thalidomide (α-phthalimido glutarimide), a new sedative hypnotic drug

    Br J Pharmacol.

    (1960)
  • E.P. Sampaio et al.

    Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes

    J Exp Med.

    (1991)
  • Cited by (191)

    • Toxicologic pathology of the reproductive system

      2022, Reproductive and Developmental Toxicology
    • Application of a human mesoderm tissue elongation system in vitro derived from human induced pluripotent stem cells to risk assessment for teratogenic chemicals

      2020, Chemosphere
      Citation Excerpt :

      Not only genetic disorders in babies but also infections in pregnant women are risks for stillbirths and congenital diseases. Developmental processes are also disturbed by exposure to various transplacental chemicals from the diet and medication of pregnant women, such as thalidomide (Matthews and McCoy, 2003). Heavy metals are also known as teratogenic risk factors during human ontogeny (Clemens and Ma, 2016; Jin et al., 2016; Vejrup et al., 2018).

    • Oral Lichen Planus and Lichenoid Lesions: Etiopathogenesis, Diagnosis and Treatment

      2023, Oral Lichen Planus and Lichenoid Lesions: Etiopathogenesis, Diagnosis and Treatment
    View all citing articles on Scopus
    View full text